News & Events
H&R Healthcare acquisition by Mediq
We are pleased to announce Mediq, the European health care products and service partner for healthcare consumers, professionals and institutions, has acquired H&R Healthcare Ltd.
“Mediq and H&R Healthcare share a passion for delivering innovation to drive improved patient outcomes while simultaneously lowering the cost of delivering healthcare. Another thing that we have in common is our focus on outstanding products that meet patients’ needs and offer excellent value to the NHS”, adds Mike Hoskins, Managing Director of H&R Healthcare. “This transaction allows H&R Healthcare to grow its business in existing markets and expand in markets such as ostomy and continence care. Also, we will leverage and build upon our mutual wound care expertise to support the ongoing education of clinicians within the medical sector and develop new innovations that improve the health and well-being of patients.”
A recognized leader in distribution of wound care products, H&R Healthcare significantly strengthens Mediq’s footprint in the UK. “Mediq is constantly innovating and investing in collaboration with healthcare providers to enable people with an illness or chronic health condition to live their lives on their own terms,” says Mediq Chief Executive Christian Wojczewski. “H&R Healthcare is the fastest growing distributor of our own brand wound care products (Kliniderm) since 2015. We look forward to working with them to provide the primary and secondary care market with the best possible products and services, specialist education and support.”
To view the press release Click here
New distribution agreement with Novaerus
H&R Healthcare have recently become the new distributors of the exciting Novaerus product range.
Novaerus is part of WellAir, an Irish company on a mission to reduce indoor airborne pollutants to create living, working, and healing spaces that foster rather than detract from human health, productivity and wellbeing. Novaerus technology has been shown to safely and effectively reduce bacteria, viruses, VOCs, and particulate matter in dozens of independent laboratory tests.
Novaerus technology has been independently tested against MS2 Bacteriophage, a commonly used surrogate for SARS-CoV* (Coronavirus). This technology was shown to reduce the virus by 99.99%.
We look forward to developing our relationship with Novaerus.
BODE – supply update
Since the outbreak of the Coronavirus our manufacturer, Bode Chemie, has received unprecedented orders for Sterillium and Bacillol 30 Tissues from around the world. This is putting significant pressure on the supply chain and means that at this time we are unfortunately unable to accept new customers for these products. Please accept our apologies.
If you would like to be contacted when our stock levels return to normal, please email firstname.lastname@example.org and state which product from the Bode range you are interested in.
NEW distribution agreements with PolyMem, AndoFlex and L-Mesitran
We are thrilled to announce three new distribution partnerships. H&R Healthcare have recently become the new distributors of PolyMem, AndoFlex and L-Mesitran. We are looking forward to working with these well respected brands.
All products will continue to be available through existing channels, including NHS Supply Chain and other ordering details will remain the same.
For more information please contact Customer Services at email@example.com.
NEW distributor agreement with Steve+
From October, H&R Healthcare are pleased to announce they will become the UK distributors of the stocking application aid, Steve+. We are excited about this new distribution agreement and how Steve+ can help many users, even with poor mobility to put on and remove their stockings.
For more information please click here.